Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Huber

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Praxis|November 24, 2004
[New study shows probiotics ineffective in prevention of post-antibiotic vaginal candidiasis]Verlag Hans Huber Bern
Praxis|November 24, 2004
[CARDS confirms usefulness of LDL lowering in type 2 diabetics]Verlag Hans Huber Bern
Methods (San Diego, Calif.)|August 6, 2013
Recombinant house dust mite allergensSusanne Vrtala, Hans Huber, Wayne R Thomas
The Journal of Allergy and Clinical Immunology|April 5, 2011
Recombinant allergens: what does the future hold?Rudolf Valenta, Katarzyna Niespodziana, Margit Focke-Tejkl, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2013
Recombinant Mal d 1 is a reliable diagnostic tool for birch pollen allergen-associated apple allergyDagmar Kollmann, Marija Geroldinger-Simic, Tamar Kinaciyan, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2017
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccinesMilena Weber, Katarzyna Niespodziana, Birgit Linhart, et al.
Optics Express|June 19, 2020
Diode-pumped cw Alexandrite laser with temporally stable 6.5 W in TEM<sub>00</sub> operation with prospect of power scalingMartin Walochnik, Bernd Jungbluth, Hans Huber, et al.
Scientific Reports|September 16, 2017
Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patientsRaffaela Campana, Katharina Moritz, Angela Neubauer, et al.
The Journal of Allergy and Clinical Immunology|September 6, 2017
Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergyTamar Kinaciyan, Birgit Nagl, Sandra Faustmann, et al.
The Journal of Allergy and Clinical Immunology|August 28, 2012
Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergyMarija Geroldinger-Simic, Tamar Kinaciyan, Birgit Nagl, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Praxis|November 24, 2004
[New study shows probiotics ineffective in prevention of post-antibiotic vaginal candidiasis]Verlag Hans Huber Bern
Praxis|November 24, 2004
[CARDS confirms usefulness of LDL lowering in type 2 diabetics]Verlag Hans Huber Bern
Methods (San Diego, Calif.)|August 6, 2013
Recombinant house dust mite allergensSusanne Vrtala, Hans Huber, Wayne R Thomas
The Journal of Allergy and Clinical Immunology|April 5, 2011
Recombinant allergens: what does the future hold?Rudolf Valenta, Katarzyna Niespodziana, Margit Focke-Tejkl, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2013
Recombinant Mal d 1 is a reliable diagnostic tool for birch pollen allergen-associated apple allergyDagmar Kollmann, Marija Geroldinger-Simic, Tamar Kinaciyan, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2017
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccinesMilena Weber, Katarzyna Niespodziana, Birgit Linhart, et al.
Optics Express|June 19, 2020
Diode-pumped cw Alexandrite laser with temporally stable 6.5 W in TEM<sub>00</sub> operation with prospect of power scalingMartin Walochnik, Bernd Jungbluth, Hans Huber, et al.
Scientific Reports|September 16, 2017
Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patientsRaffaela Campana, Katharina Moritz, Angela Neubauer, et al.
The Journal of Allergy and Clinical Immunology|September 6, 2017
Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergyTamar Kinaciyan, Birgit Nagl, Sandra Faustmann, et al.
The Journal of Allergy and Clinical Immunology|August 28, 2012
Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergyMarija Geroldinger-Simic, Tamar Kinaciyan, Birgit Nagl, et al.
Pageof 2